-26.0%
FSLR vs MRNA
+945.0%
-971.0%
-47.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.6% | +13.1% | -8.5% | +4.3% |
| 7D | +10.3% | +20.6% | -10.3% | +9.9% |
| 30D | +10.4% | +27.1% | -16.7% | +9.8% |
| 3M | -20.2% | +353.4% | -373.5% | -24.3% |
| 6M | -8.0% | +446.3% | -454.2% | -16.0% |
| YTD | -25.5% | +776.2% | -801.7% | -39.3% |
| 1Y | -26.0% | +987.9% | -1,013.9% | -41.1% |
| All | -26.0% | +945.0% | -971.0% | -41.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling